Excipient Risk Assessment: Applying the EU Guidelines on Appropriate GMP for Excipients

Excipients make up most of the mass of many medicines, yet they are often the least scrutinised part of the supply chain. Since 2016, EU law has required every manufacturing authorisation holder to formally assess the risk each excipient presents and to decide what level of good manufacturing practice its supplier must apply. Inspectors increasingly ask to see that assessment, and a generic template rarely satisfies them.

The legal basis

Article 46(f) of Directive 2001/83/EC obliges the manufacturing authorisation holder to ensure that excipients are suitable for use by ascertaining what the appropriate GMP is. The European Commission set out how to do this in its Guidelines of 19 March 2015 on the formalised risk assessment for ascertaining the appropriate good manufacturing practice for excipients of medicinal products for human use (2015/C 95/02). For excipients in authorised products, the assessment was expected to be completed by 21 March 2016, and it must be kept up to date thereafter.

The responsibility sits with the manufacturing authorisation holder, not with the excipient supplier. The documentation must be available at the manufacturing site for review by GMP inspectors, and the process should be embedded in the pharmaceutical quality system rather than run as a one-off exercise.

Step one: what GMP does this excipient need?

The guidelines ask companies to use ICH Q9 quality risk management tools to assess the risk each excipient presents to the quality, safety and function of the finished product. Factors include:

  • Source-related risks such as TSE, viral contamination, microbial or endotoxin contamination and impurities from raw materials or processing (for example residual solvents)
  • Sterility assurance where the excipient is claimed or required to be sterile
  • Cross-contamination from shared equipment, supply chain complexity, storage conditions, stability and packaging integrity
  • How the excipient is used: the dosage form and route, its function in the formulation, its proportion in the composition and the daily patient intake
  • Known quality defects or fraudulent adulteration, and whether it is a composite or affects critical quality attributes

From this, the company identifies which elements of EudraLex Volume 4 are needed to control the excipient’s quality. A coating agent in a solid oral tablet and an excipient in a parenteral product will warrant very different expectations.

Step two: can this supplier deliver it?

The required GMP is then compared with what the excipient manufacturer actually does. Evidence may come from audits, questionnaires and documentation supplied by the manufacturer, and recognised third-party certifications can be taken into account. Gaps are documented, and the manufacturer is assigned a risk profile, typically low, medium or high.

The outcome drives a control strategy: accepting the supplier as is, adding controls such as on-site audits, additional testing or tighter documentation, or concluding that the supplier is unacceptable for that use.

Step three: keep it current

An excipient risk assessment is a living document. The guidelines expect ongoing review using indicators such as batch defects and their severity, quality trends in the excipient and the finished product, changes to the supplier’s process, loss of certification and the results of audits or re-audits. Where the picture changes, the control strategy should change with it, and any resulting supplier change should flow through change control and, where relevant, the variations system.

Where companies fall short

  • One assessment covering an excipient across products, ignoring differences in route and dose
  • Reliance on certificates of analysis without any evidence about the manufacturer’s actual GMP
  • Distributors and brokers treated as the manufacturer, leaving the real production site unassessed
  • Assessments completed in 2016 and never revisited

How PQRA helps

PQRA supports manufacturers and marketing authorisation holders in Greece and across the EU with excipient risk assessment methodology, supplier qualification and audits, gap analyses against the Commission guidelines, and preparation for EOF and other EU GMP inspections. We help you build an assessment that reflects how each excipient is really used, and a review cycle that keeps it defensible.

Talk to PQRA about your excipient risk assessments

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *